Head In The Game – IHL Files Patent For CBD-Based Head Trauma Medicine

Impression Healthcare (ASX: IHL) has filed a patent for its novel cannabinoid formula known as IHL-216A, which is designed to be used as a neuroprotective agent subsequent to head trauma.

Impression Healthcare (ASX: IHL) is seeking a patent for one of its four novel cannabinoid formulas, which the company's drug discovery team believes will assist with Traumatic Brain Injury (TBI.)

The team argues that the correct administration of the drug following a head injury will help to reduce neuronal cell death and damage, which is a growing concern to many athletes worldwide.

Traumatic Brain Injury, according to IHL, accounts for 10 million deaths/hospitalizations globally each year. Despite the prevalence of TBI, however, there are no existing pharmaceutical agents which have currently been approved to treat it.

Once a Traumatic Brain Injury occurs, IHL argues that their neuroprotective cannabinoid drug should be the first response for medical professionals, in order to reduce neuro-excitation, neuro-inflammation, cerebral blood flow, and cerebral oxygen consumption.

There is a clear need for a post-injury treatment as the personal and societal costs of TBI are enormous.

IHL's Chief Medical Officer, Sud Agarwal

"As a neurosurgeon of 16 years standing, I am hopeful that IHL – 216A will be a game-changer in the pharmacological treatment of traumatic brain injury which is a ubiquitous world problem," said Dr Ron Jithoo, specialist neurosurgeon and Impression's medical advisory board member.

The brain injury drug is just one of four drugs in IHL's pipeline, with the others designed for Obstructive sleep apnoea, Gum disease, and Temporomandibular joint disorder.

IHL has its Australian licenses in place, and also has access to robust distribution pathways, thanks to Cannvalate, Australia's largest distribution network of cannabis prescribers.

Should trials be successful for these four novel formulas, IHL will have tapped into four major global markets.

You can read the original press release here, as well as access IHL's company profile here.

Exclusive Interview With Cannvalate CEO Dr. Sud Agarwal

The Green Fund sits down for an exclusive interview with Dr. Sud Agarwal to discuss his career, his company and his recent appointment to Impression Healthcare. It's been a mammoth year for Impression...
Read More

Subscribe Now
& Keep Up to Date

Get the latest pot stock recommendations, cannabis news
and industry updates straight to your inbox!

Louis O'Neill
Louis O'Neill

Louis is a writer based in Sydney with a focus on social and political issues. Having interviewed local politicians and entrepreneurs, Louis now focuses on cannabis culture, legislation & reform.

Leave a Reply

Your email address will not be published. Required fields are marked *